PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Long-term risks of targeted therapies

New data on cancer and cardiovascular risks

2023-06-01
(Press-News.org) Janus kinase inhibitors (JAKi) and biologics are the cornerstone of modern treatment for rheumatoid arthritis (RA). But there have been concerns over long-term side effects. New data from a national healthcare database offer reassuring findings for overall cancers and cardiovascular disease (CVD).

Patients with inflammatory rheumatic diseases have an increased risk of CVD compared to the general population.1 In acknowledgement of this, EULAR – the European Alliance of Associations for Rheumatology – has published recommendations for cardiovascular risk management in patients with a range of rheumatic and musculoskeletal diseases, including RA.2,3

At the 2023 EULAR annual congress, Ahn and colleagues present data on the risks of cancer and CVD in people with seropositive RA (SPRA) who had been treated with JAKi or biologics. Information was collected for over 100,000 people who had a case of new-onset SPRA logged between 2010–2020 in the national healthcare database of the Republic of South Korea.

The research then looked for events of overall and site-specific cancers and CVD outcomes, including deep vein thrombosis, pulmonary embolism, and composite cardiovascular events.

The results showed that – compared with people who received only conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) – the incidence rate ratio of overall cancers and CVD in those receiving JAKi or biologics were 0.88 and 0.91, respectively. JAKi did not confer a greater risk of overall CVD or cancer compared with other biologics or csDMARDs. This means overall cancer and CVD incidence were not increased in people with SPRA treated with JAKi/biologics, and were relatively lower than in csDMARD-only patients, underscoring the need for optimal control of disease activity in order to mitigate risks.

However, the authors note that site-specific lung, liver, prostate, and skin cancers were more frequent in people using JAKi/biologics – a finding which requires further investigation. “Overall, this work is reassuring with regards to overall cancers and CVD, but there is a need to keep collecting data in order to support risk management in clinical practice,” says lead author Sung Soo Ahn.

Source:
Ahn SS, et al. Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors and biologics. Presented at EULAR 2023; Abstract OP0132.

References:
1. England BR, Thiele GM, Anderson DR, et al. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018;361:k1036.

2. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17–28.

3. Drosos GC, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 2022;81:768–79.

About EULAR
EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.

Contact
EULAR Communications, communications@eular.org

Notes to Editors
EULAR Recommendations
EULAR School of Rheumatology
EULAR Press Releases

END


ELSE PRESS RELEASES FROM THIS DATE:

Managing anxiety and depression in arthritis

2023-06-01
Anxiety and depression are the mental health issues most commonly associated with inflammatory arthritis, and it is well-established that there is a link between mental health issues and poor health outcomes.2 The EULAR recommendations emphasize the need to assess mental health regularly;1 however, little is known about the association between self-management and mental health in people with inflammatory arthritis. At the 2023 EULAR congress, Vestergaard and colleagues report on their cross-sectional study in Denmark. This included 42,407 adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or spondylarthritis (axSpA). The aim was to find ...

Healthy lifestyle and mortality in osteoarthritis

2023-06-01
In this work, data from the UK Biobank were used to investigate the association of both individual and combined healthy lifestyle factors with the risk of all-cause and cause-specific mortality among 104,142 people with osteoarthritis. The researchers gave each person a score for their lifestyle, based on their body mass index (BMI) and self-reported diet, sleep duration, physical activity, sedentary time, social connection, smoking, and alcohol drinking – all factors thought to be associated with health. Overall, there were 9,915 deaths recorded after the first 2 years’ ...

The European Alliance of Associations For Rheumatology, EULAR, announces its strategy for 2024 – 2028

2023-06-01
Over the period 2018 – 2023, EULAR, the leading organisation in RMDs, has grown substantially and has been professionalised in every aspect. For example, EULAR has increased its impact on RMDs through the development of new services provided by the EULAR Research Centre (ERC). Despite the disruption of routine procedures brought about by the pandemic, EULAR overcame the substantial associated challenges, providing continued access to education and networking for the RMD community. “We have made tremendous progress by setting up two virtual congresses and one fully hybrid congress, and we have ...

EULAR launches ‘RheumaFacts’, a unique and Pan-European data repository of rheumatic and musculoskeletal disease indicators

2023-06-01
The European Alliance of Associations for Rheumatology (EULAR) is proud to announce the launch of RheumaFacts, an innovative and unique resource of facts and figures related to rheumatic and musculoskeletal diseases (RMDs) across Europe. Strategically developed to support EULAR’s mission of reducing the impact of RMDs on individuals and society, RheumaFacts will serve as a powerful tool to provide healthcare professionals, researchers, policymakers, and patients with data-driven insights on the status of rheumatologic care across EULAR’s ...

EULAR launches first European patient-filled survey about the impact of rheumatic and musculoskeletal diseases on individual’s lives

2023-06-01
The European Alliance of Associations for Rheumatology (EULAR) has announced the launch of the EULAR Impact of RMDs Survey, an online questionnaire targeted directly at RMD patients. The data collected through this survey will be an important resource for researchers, healthcare professionals, and patients alike, providing a comprehensive database of patient-reported outcomes on their healthcare situation, and how the illness affects their social and occupational lives. By collecting and analysing data from a large number of patients with RMDs on a recurring basis, the survey will provide valuable insights into the burden of disease and help improve the overall care for people living with ...

Rheumatic and musculoskeletal diseases (RMDs) often accelerate lethal comorbidities

2023-06-01
Rheumatic and musculoskeletal diseases (RMDs) include over 200 diseases that affect over 120 million Europeans of all ages. Aside from the significant direct impact RMDs have on patients, many of them also pose a further significant risk to the population by virtue of accelerating many comorbidities if the RMD is not treated appropriately. The most significant comorbidities of inflammatory RMDs include cardiovascular disease, lung disease, cancers, gastrointestinal disease, and mental health disorders.[1] Many of these comorbidities are prioritised by the EU as key non-communicable ...

Stand Up to Cancer announces $1.5 million commitment from Pancreatic Cancer North America to fund pancreatic cancer vaccine research

Stand Up to Cancer announces $1.5 million commitment from Pancreatic Cancer North America to fund pancreatic cancer vaccine research
2023-06-01
LOS ANGELES – June 1, 2023 – Stand Up To Cancer® (SU2C) and Pancreatic Cancer North America (PCNA) today announced that PCNA will contribute $1.5 million to SU2C in support of critically needed research focused on pancreatic cancer, which has the highest mortality rate of all major cancers.      One of the projects supported by PCNA will include a correlative study that analyzes data from a previous Phase 1 clinical trial conducted by a Research Team funded through the SU2C Convergence program and led by researchers at Memorial ...

Rethink, rewrite, redefine—how biodegradable plastics are reshaping sustainability

Rethink, rewrite, redefine—how biodegradable plastics are reshaping sustainability
2023-06-01
The University of California San Diego’s vision is to be a student-centered, research-focused, service-oriented public university. There are countless examples across campus of the ways these three pillars are upheld, but it is unique to find all three incorporated at once. Now a new book on algae-based biodegradable plastics showcases student research and the monumental potential it has to change consumerism on a global scale. Statistics on the environmental damage of plastics are stark: in 2018, U.S. landfills received 27 million tons of plastic (U.S. Environmental Protection Agency); ...

ComboMATCH investigators are translating robust pre-clinical evidence for new anti-cancer drug combinations into a series of early-phase clinical trials

2023-06-01
Five leading cancer research organizations in the United States are jointly announcing the start of patient enrollment in Molecular Analysis for Combination Therapy Choice (ComboMATCH), a unique, precision medicine initiative to test new combinations of cancer drugs guided by tumor biology. The Alliance for Clinical Trials in Oncology, Children's Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network plan to conduct many early-phase treatment trials through this platform in collaboration with the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). NCI is part of ...

Parkinson’s disease drug ropinirole safely slowed the progression of ALS for over 6 months in a clinical trial

Parkinson’s disease drug ropinirole safely slowed the progression of ALS for over 6 months in a clinical trial
2023-06-01
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a fatal motor neuron disease that causes people to gradually lose control of their muscles. There is no cure, and current treatments focus on reducing symptoms and providing supportive care. Reporting June 1 in the journal Cell Stem Cell, researchers from Japan show in an early clinical trial that the Parkinson’s disease drug ropinirole is safe to use in ALS patients and delayed disease progression by 27.9 weeks on average. Some patients were more responsive to ropinirole treatment than others, and the researchers ...

LAST 30 PRESS RELEASES:

Do sweeteners increase your appetite? New evidence from randomised controlled trial says no 

Women with obesity do not need to gain weight during pregnancy, new study suggests

Individuals with multiple sclerosis face substantially greater risk of hospitalisation and death from COVID-19, despite high rates of vaccination

Study shows obesity in childhood associated with a more than doubling of risk of developing multiple sclerosis in early adulthood

Rice Emerging Scholars Program receives $2.5M NSF grant to boost STEM education

Virtual rehabilitation provides benefits for stroke recovery

Generative AI develops potential new drugs for antibiotic-resistant bacteria

Biofuels could help island nations survive a global catastrophe, study suggests

NJIT research team discovering how fluids behave in nanopores with NSF grant

New study shows association of historical housing discrimination and shortfalls in colon cancer treatment

Social media use may help to empower plastic surgery patients

Q&A: How to train AI when you don't have enough data

Wayne State University researchers uncover potential treatment targets for Zika virus-related eye abnormalities

Discovering Van Gogh in the wild: scientists unveil a new gecko species

Small birds spice up the already diverse diet of spotted hyenas in Namibia

Imaging detects transient “hypoxic pockets” in the mouse brain

Dissolved organic matter could be used to track and improve the health of freshwaters

Indoor air quality standards in public buildings would boost health and economy, say international experts

Positive associations between premenstrual disorders and perinatal depression

New imaging method illuminates oxygen's journey in the brain

Researchers discover key gene for toxic alkaloid in barley

New approach to monitoring freshwater quality can identify sources of pollution, and predict their effects

Bidirectional link between premenstrual disorders and perinatal depression

Cell division quality control ‘stopwatch’ uncovered

Vaccine protects cattle from bovine tuberculosis, may eliminate disease

Andrew Siemion to receive the SETI Institute’s 2024 Drake Award

New study shows how the Crimean-Congo hemorrhagic fever virus enters our cells

Neoadjuvant chemotherapy proves effective for locally advanced penile squamous cell carcinoma

Study flips treatment paradigm in bilateral Wilms tumor, shows resistance to chemotherapy may point toward favorable outcomes

Doctors received approximately $12.1 billion from drug and device makers between 2013-2022

[Press-News.org] Long-term risks of targeted therapies
New data on cancer and cardiovascular risks